Abstract

BackgroundAn assessment of cardiac events and survival using quantitative gated myocardial single-photon emission computed tomography (SPECT) (J-ACCESS) associated several risk factors with cardiac events in Japan. The clinical course after revascularization and/or optimal medical therapy (OMT) was followed in patients with coronary artery disease (CAD) at moderate-to-high risk estimated by software incorporating the J-ACCESS risk model. The present study aimed to determine the relevance of changes in estimated risk to outcomes of these therapies.MethodsThis study included 494 patients with possible or definite CAD who underwent initial pharmacological stress 99mTc-tetrofosmin myocardial perfusion SPECT (MPS) before and eight months after therapy. Major cardiac event risk during 3 years of follow-up was calculated using an equation based on that in the J-ACCESS study. Patients with ≥ 10% cardiac event risk estimated at the first MPS (n = 31) were analyzed and followed up for at least 1 year.ResultsEstimated risk was reduced by ≥ 5% in 14 patients (45%) after therapy. During a follow-up period of 22.1 ± 6.7 months, one patient without such reduction had a major cardiac event. Mean %summed stress scores significantly decreased from baseline to follow-up in patients with and without risk reduction. Left ventricular ejection fraction (LVEF [%]) at rest was significantly increased at the second, compared with the first MPS between patients with, than without risk reduction (57 ± 17 vs. 45 ± 16%, p = 0.001 and 50 ± 11 vs. 49 ± 9%, p = 0.953, respectively).ConclusionsA reduction in cardiac ischemia and an increase in LVEF by revascularization and/or OMT were necessary to avoid cardiac events among patients with moderate-to-high estimated risk, and changes in event risk were quantifiable.

Highlights

  • For several decades, percutaneous coronary intervention (PCI) has been the main therapeutic method for treating patients with coronary artery disease (CAD) associated with myocardial ischemia

  • Among 494 patients, 31 with ≥ 10% probability of cardiac events at the first myocardial perfusion SPECT (MPS) were defined as being a moderateto-high risk, and they were analyzed in a follow-up study

  • The Left ventricular ejection fraction (LVEF) at rest was significantly increased at the second, compared with the first study in patients with, but not in those without ≥ 5% risk reduction (57 ± 17 vs. 45 ± 16%, p < 0.001 and 50 ± 11 vs. 49 ± 9%, p = 0.953, respectively)

Read more

Summary

Introduction

Percutaneous coronary intervention (PCI) has been the main therapeutic method for treating patients with coronary artery disease (CAD) associated with myocardial ischemia. A nuclear substudy of the COURAGE trial of 314 patients who underwent myocardial perfusion single photon emission-computed tomography (SPECT) before and after PCI found significant ischemic reductions in patients treated with OMT in addition to PCI [5]. The clinical course after revascularization and/or optimal medical therapy (OMT) was followed in patients with coronary artery disease (CAD) at moderate-to-high risk estimated by software incorporating the J-ACCESS risk model. Methods This study included 494 patients with possible or definite CAD who underwent initial pharmacological stress 99mTc-tetrofosmin myocardial perfusion SPECT (MPS) before and eight months after therapy. Conclusions A reduction in cardiac ischemia and an increase in LVEF by revascularization and/or OMT were necessary to avoid cardiac events among patients with moderate-to-high estimated risk, and changes in event risk were quantifiable

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.